MedTrace Logo

Study of ANX007 in Participants With Primary Open-angle Glaucoma

NCT04188015 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2020-08-20

No results posted yet for this study

Summary

This is a double-masked, randomized, sham-controlled study evaluating two dose levels of ANX007 vs sham, administered as repeat Intravitreal (IVT) injections in patients with Primary Open-angle Glaucoma.

Conditions

Interventions

BIOLOGICAL

2.5mg ANX007

A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.

BIOLOGICAL

5.0mg ANX007

A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.

OTHER

Sham Procedure

The sham injection is preformed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of a syringe without a needle.

Sponsors & Collaborators

  • Annexon, Inc.

    lead INDUSTRY

Principal Investigators

  • Eric Humphriss · Annexon Biosciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-25
Primary Completion
2019-06-03
Completion
2019-06-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04188015 on ClinicalTrials.gov